JPmorgan reduces Sarepta (SRPT) PT and holds an overweight evaluation

Sarepta Therapeutics, Inc. (Nasdaq: Srpt) is one of the 10 best small cap shares that can buy according to the billionaires. On July 10th, JPMorgan reduced his price for Sarepta Therapeutics, Inc. (Nasdaq: SRPT) from $ 28 to $ 28, but contributed an “overweight” rating.

JPmorgan emphasized that there is an “evaluation interruption” and that the current share price does not completely reflect the company's long -term value.

A laboratory technician in a white layer with a microscope and examines a bottle of biopharmaceuticals.

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) has three treatments for Duchenne Muskeldystrophy (DMD) approved by the FDA with suitable mutations. These treatments are known as Exondys 51, Vyondys 53 and Amondys 45.

In addition, JPMorgan analysts found that the company's gene therapy, Elevidys, has full approval for use in all outpatient DMD patients.

According to JPMorgan, the company's gene therapy is currently the full approval for all outpatient DMD patients. However, Elefidys still holds the accelerated admission status, while Sarepta Therapeutics, Inc. (Nasdaq: SRPT) continues the discussions with the FDA.

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a company for medical research and drug development companies that focus on the development of genetic drugs for rare diseases. The company has leading positions in Duchenne Muskeldystrophy (DMD) and muscular dystrophies with limbs (LGMD).

While we recognize the potential of SRPT as an investment, we believe that certain AI shares offer higher upward potential and form a less downward risk. If you are looking for an extremely undervalued AI population that also benefits significantly from tariffs from the Trump era and the onshoring trend, you will find our free report on the Best short-term AI.

Read next: 10 best American semiconductor shares to buy now And 11 Best Fintech shares that can currently buy.

Disclosure: none. This article is originally published at Insider Monkey.